Management of Hyperkalemia in Patients on Spironolactone

Immediate Management

• The European Society of Cardiology recommends administering intravenous calcium (calcium gluconate 10%: 15-30 mL or calcium chloride 10%: 5-10 mL) over 2-5 minutes to stabilize cardiac membranes in patients with severe hyperkalemia (≥6.5 mEq/L or with ECG changes) 2, 3
• Insulin with glucose (10 units regular insulin IV with 25g glucose) should be given to shift potassium into cells, with onset within 15-30 minutes and effects lasting 4-6 hours 3
• Nebulized beta-2 agonists (albuterol 10-20 mg) can be considered as an adjunctive therapy to enhance intracellular potassium shifting 2, 3
• Sodium bicarbonate (50 mEq IV) should only be used if concurrent metabolic acidosis is present 3, 4

Long-term Management

• Loop diuretics (furosemide 40-80 mg IV/oral) can be administered to increase renal potassium excretion if renal function is adequate 2, 3
• Potassium binders such as sodium polystyrene sulfonate (15-50g orally/rectally), patiromer, or sodium zirconium cyclosilicate can be initiated to enhance fecal potassium excretion 2, 5
• Hemodialysis can be considered for severe cases, especially in patients with renal failure 2, 3

Monitoring and Prevention

• The American College of Cardiology recommends checking serum potassium and renal function within 3 days after initiating treatment, and continuing monitoring at least weekly for the first month, then monthly for the first 3 months 6, 7
• Patients should be educated to avoid high-potassium foods and potassium-containing salt substitutes 8, 7
• The European Heart Journal suggests that patients with heart failure may benefit from continuation of RAAS inhibitors despite mild hyperkalemia (5.0-5.5 mEq/L) 1, 5
• Patiromer or sodium zirconium cyclosilicate can be considered for chronic management of hyperkalemia in patients who require continuation of RAAS inhibitors 2, 4